Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top and bottom lines: revenue $1.05M vs. $1.88M expected, and GAAP EPS of -$0.23 vs. -$0.22 expected. The revenue miss was driven by timing-related delays in collaboration activities with Amgen. While R&D and G&A expenses decreased YoY due to strategic prioritization of the heme program, a drop in interest income widened the net loss beyond expectations. Cash runway is guided into Q2 FY27, though debt amortization starts in Q4 2026 due to missed milestones.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: TScan Therapeutics(TCRX) the Revenue is 1.051 M (-65.83%), Miss estimate;the EBIT is -30.49 M (+21.11%), Miss estimate;the EPS is -0.23 (+17.86%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B65.83%
0.00B39.04%
-0.00B26.79%
EBITMiss expectations
-0.03B21.11%
-0.03B24.39%
-0.00B3.28%
EPSMiss expectations
-0.2317.86%
-0.21523.21%
-0.01505.35%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf